This HTML5 document contains 181 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n12http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q33627763
rdf:type
wikibase:Item
schema:description
vitenskapelig artikkel 2009年论文 наукова стаття, опублікована в листопаді 2009 мақолаи илмӣ 2009年论文 2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած سائنسی مضمون mokslinis straipsnis artículo científico publicado en 2009 artículu científicu espublizáu en 2009 vitskapeleg artikkel tieteellinen artikkeli 2009年论文 artikulong pang-agham научна статия videnskabelig artikel (udgivet 2009) 2009年論文 επιστημονικό άρθρο 2009年论文 artigo científico (publicado na 2009) научни чланак bilimsel makale מאמר מדעי სამეცნიერო სტატია 2009년 논문 2009 nî lūn-bûn 2009年論文 2009 թվականի նոյեմբերին հրատարակված գիտական հոդված artykuł naukowy مقالة علمية vědecký článek article scientifique (publié 2009) 2009年の論文 wissenschaftlicher Artikel teaduslik artikkel 2009年論文 vetenskaplig artikel artigo científico (publicado na 2009) научная статья 2009年論文 articol științific ২০০৯-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ vedecký článok naučni članak 2009年论文 tudományos cikk artikull shkencor bài báo khoa học مقالهٔ علمی article scientific научни чланак scientific article บทความทางวิทยาศาสตร์ 2009年論文 scienca artikolo мақолаи илмӣ wetenschappelijk artikel 2009年论文 artigo científico article científic articolo scientifico
p:P577
wds:Q33627763-781B9D7B-01C6-4691-8103-2C3504BED21C
wdt:P577
2009-11-30T00:00:00Z
p:P407
wds:Q33627763-32B528B2-C674-4861-8E80-EB78D2C03AA3
wdt:P407
wd:Q1860
p:P2860
wds:Q33627763-C9F91A73-7AF4-40FE-B562-41F3CB37FA44 wds:Q33627763-CAA270EA-E618-449F-9F29-B90AF8DD09D9 wds:Q33627763-CAF194A3-34CF-4FE1-BEAD-EB708789990B wds:Q33627763-CD0204CF-4045-4391-AAB1-5EF5481CB14C wds:Q33627763-D23D85F2-B8B6-44EF-94F3-249EBC7E77A4 wds:Q33627763-D715D2AC-B2E5-4664-977F-D4F2B891294F wds:Q33627763-AABD67BF-02CE-46AC-8175-470849D556D2 wds:Q33627763-C21114FE-1619-45C9-88AE-5FB558FC2468 wds:Q33627763-957FBCC8-E895-43D8-9600-5315237EAB98 wds:Q33627763-95DEDDB1-EED8-4134-B70C-335B2BAB5ABF wds:Q33627763-9960F3DF-4A93-494B-AE98-8BEBD3889920 wds:Q33627763-3165972E-4EA6-4070-926A-2613EFEA0F51 wds:Q33627763-9A8D0242-E5ED-43B0-BDAB-FDF7B2F61BA2 wds:Q33627763-9B7C858F-C56C-425D-8B09-9B26FB4FFAB9 wds:Q33627763-5E1CBC34-AEDD-449C-8390-78E43FA362F6 wds:Q33627763-3B54857A-E1AA-4BF1-9608-C9E6E0CC2E21 wds:Q33627763-42084406-3288-42B6-8DAA-2349DE361398 wds:Q33627763-6D23A3B7-B85F-40C7-82EC-AB02669FD5E4 wds:Q33627763-7CC270B6-6C53-40B1-9F9C-8DEEDC532A26 wds:Q33627763-5CC7EF39-D79E-45AF-9D5D-D3352CA802C0 wds:Q33627763-23B087D6-E8CC-4217-94D4-62DFDD110402 wds:Q33627763-25683C5C-8803-4AE5-9AF2-01784650155D wds:Q33627763-2C86253D-466A-4A96-BD37-A4C2071E5FD3 wds:Q33627763-30855872-1F08-40E2-AE45-1DD16A2C03C5
wdt:P2860
wd:Q24535043 wd:Q44601128 wd:Q70685636 wd:Q75726399 wd:Q36342350 wd:Q44393459 wd:Q69614850 wd:Q41866566 wd:Q36276765 wd:Q34096365 wd:Q28278736 wd:Q27860904 wd:Q48797418 wd:Q29614302 wd:Q33744660 wd:Q29614938 wd:Q34425283 wd:Q71232777 wd:Q27860681 wd:Q34578752 wd:Q71751782 wd:Q29615946 wd:Q35823939 wd:Q70487576
p:P2093
wds:Q33627763-50AF593F-23D6-4B53-93A5-D38F3355D5A4 wds:Q33627763-466488AD-C71C-4AE1-B2C0-BCF6FF3E1B1C wds:Q33627763-3AEF2F34-7B49-4E9D-A355-8207367CB07D wds:Q33627763-F05F4985-2746-45B9-973C-6004C54C9264 wds:Q33627763-F1793735-0049-4118-B987-F4E50DC58421 wds:Q33627763-D95CBED3-7693-43E9-BD55-563C3CD6CFE5 wds:Q33627763-ED5D4A1C-25F8-4789-B4ED-90FA106DD4C6 wds:Q33627763-0F42DA9A-B715-4D30-9954-69182950862F wds:Q33627763-0B21EC55-AE24-425A-9A83-0BA5FE6448E6 wds:Q33627763-8F21DBC4-2692-45AA-BCB8-C3C8918EA667 wds:Q33627763-87E895B5-8BA6-4543-95AC-8A0E860850B3 wds:Q33627763-B23BB26C-1BB9-4D1F-B7A4-1BC65B578AF9 wds:Q33627763-A2AEB712-D6FC-421C-9087-4F5179B846C0 wds:Q33627763-9BF6F2B1-0BEC-4448-BF0E-92B01FAD3E09 wds:Q33627763-9DA5F65E-C4CF-4170-99D0-B77F8DC6A31C
wdt:P2093
William P Tew Lawrence H Schwartz Jakob Dupont Mace L Rothenberg Ric Andal Lars Sternas Giliane Buzenet Wendy Cooper A Craig Lockhart Elizabeth Koehler Jeffrey A Sosman David R Spriggs Paul Chevalier Isabelle Dancy Jason A Koutcher
rdfs:label
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.
skos:prefLabel
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.
schema:name
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.
p:P50
wds:Q33627763-BEB610D9-66A4-4D07-895C-ECFC3F4707B1 wds:Q33627763-C39FD706-5E78-4940-8A29-0CB7BE821AAE
wdt:P50
wd:Q59563682 wd:Q51111933
p:P1476
wds:Q33627763-005AEB73-07DB-4A63-B085-C817B73EC621
wdt:P1476
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors
p:P304
wds:Q33627763-08C4549A-E60A-485A-8291-B53D9FFC1DFE
wdt:P304
207-214
p:P31
wds:Q33627763-006160D7-5659-4014-963F-FB5D67DC7FFA
wdt:P31
wd:Q13442814
p:P921
wds:Q33627763-CF9064BF-785C-4289-96BB-BE8F99741B36 wds:Q33627763-6B9C6D6D-CE3C-4400-8A4F-6C0710BCF7EF
wdt:P921
wd:Q111140 wd:Q4689286
p:P698
wds:Q33627763-61B7A963-257E-4C37-804B-2D255CDF2C42
wdtn:P698
n11:19949018
wdt:P698
19949018
p:P1433
wds:Q33627763-B7CCCF28-2265-4BE3-BBEC-B01412414800
wdt:P1433
wd:Q400292
p:P433
wds:Q33627763-8E6CF2C5-974E-4737-9B38-C5A679769D66
p:P478
wds:Q33627763-95260A5B-7786-4D67-85BF-41BFA662C77F
wdt:P433
2
wdt:P478
28
p:P356
wds:Q33627763-8EA00321-CBB4-499F-829D-D43BDBE2245B
wdtn:P356
n12:JCO.2009.22.9237
wdt:P356
10.1200/JCO.2009.22.9237
p:P932
wds:Q33627763-12D6540B-115B-4197-B4E9-2E7D58DCF2A7
wdt:P932
2815710